Market Place
Sourcing Support
Bridgebio CEO Shrugs Off Recent Attruby Pricing Pressure Fears
25 Feb 2026 //
FIERCE PHARMA
Synechron`s Calitii Lands Managed Services Deal With Bridgebio
20 Jan 2026 //
PHARMIWEB
BridgeBio Prices $550M 2033 Notes to Pre-Fund 2027 Debt
16 Jan 2026 //
GLOBENEWSWIRE
Bridgebio To Participate In The J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Bridgebio To Host Achondroplasia Investor Webinar On January 9Th
02 Jan 2026 //
GLOBENEWSWIRE
Is Pfizer`s Recent ATTR Sales Decline In The US A Warning Sign?
02 Dec 2025 //
FIERCE PHARMA
Bridgebio To Participate In December Investor Conferences
25 Nov 2025 //
GLOBENEWSWIRE
Pfizer`s Challenge Of Bridgebio Ads Referred To Federal Agencies
10 Nov 2025 //
FIERCE PHARMA
Acoramidis Cuts All-Cause Mortality In ATTR-CM Including V142I
08 Nov 2025 //
GLOBENEWSWIRE
Bridgebio To Participate In November Investor Conferences
04 Nov 2025 //
GLOBENEWSWIRE
Bridgebio Unveils Q3 2025 Financials and Business Progress
29 Oct 2025 //
GLOBENEWSWIRE
Acoramidis Reduces CV Outcomes In ATTR-CM Within First Month
28 Sep 2025 //
GLOBENEWSWIRE
BridgeBio Announces Inducement Grants Under Nasdaq 5635(c)(4)
10 Sep 2025 //
GLOBENEWSWIRE
BridgeBio Plans Investor Webinar for Autosomal ADH1
03 Sep 2025 //
GLOBENEWSWIRE
BridgeBio to Unveil Encaleret Phase 2 Data in Post-Surgical
02 Sep 2025 //
GLOBENEWSWIRE
BridgeBio to Participate in September Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Bridge Bio Reports Q2 2025 Financial Results and Business Updates
05 Aug 2025 //
GLOBENEWSWIRE
BridgeBio Raises $300M Through Capped Monetization of Beyonttra
30 Jun 2025 //
GLOBENEWSWIRE
BridgeBio to Attend Goldman Sachs Healthcare Conference 2025
02 Jun 2025 //
GLOBENEWSWIRE
Acoramidis Reduces Atrial Fibrillation in ATTR-CM Patients
20 May 2025 //
GLOBENEWSWIRE
Acoramidis Linked to Survival in ATTRibute-CM Study
19 May 2025 //
GLOBENEWSWIRE
BridgeBio Reports Inducement Grants under Nasdaq LR 5635(c)(4)
14 May 2025 //
GLOBENEWSWIRE
First Participant Dosed with Acoramidis in ACT-EARLY Study
13 May 2025 //
GLOBENEWSWIRE
BridgeBio to Share ATTR-CM Data at Heart Congress
12 May 2025 //
GLOBENEWSWIRE
BridgeBio`s Attruby has `found a place` in ATTR-CM market: CEO
30 Apr 2025 //
FIERCE PHARMA
BridgeBio reports Q1 2025 financial results and updates
29 Apr 2025 //
GLOBENEWSWIRE
Beyonttra Approved by UK MHRA to Treat ATTR-CM
28 Apr 2025 //
GLOBENEWSWIRE
BridgeBio to Host Q1 2025 Financial Results Call on April 29
22 Apr 2025 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
11 Apr 2025 //
GLOBENEWSWIRE
Acoramidis Improves Cardiovascular Outcomes in Variant ATTR-CM
31 Mar 2025 //
GLOBENEWSWIRE
Beyonttra™ (acoramidis) Approved in Japan to Treat ATTR-CM
27 Mar 2025 //
GLOBENEWSWIRE
BridgeBio Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
21 Mar 2025 //
GLOBENEWSWIRE
BridgeBio starts debt management strategy, plans convertible note
24 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Reports Q4, Full-Year 2024 Results & Commercial Update
20 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Pharma to Report Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
GLOBENEWSWIRE
EU Approves BEYONTTRA, A Near-Complete TTR Stabilizer For ATTR-CM
11 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Announce Commercial Progress, Updates, & 2025 Milestones
13 Jan 2025 //
GLOBENEWSWIRE
BridgeBio Gets FDA Fast Track For BBO-8520 In KRAS-Mutated Cancer
09 Jan 2025 //
BUSINESSWIRE
BridgeBio to Participate in J.P. Morgan Healthcare Conference
08 Jan 2025 //
GLOBENEWSWIRE
Acoramidis Gets Positive CHMP Nod For ATTR-CM Treatment
13 Dec 2024 //
GLOBENEWSWIRE
Orsini Selected by BridgeBio as Pharmacy for ATTRUBY™ Treatment
25 Nov 2024 //
PR NEWSWIRE
Look out, Pfizer: BridgeBio gains `best-case` FDA nod for Attruby
25 Nov 2024 //
FIERCE PHARMA
BridgeBio Oncology Appoints Praveen to its Board of Directors
18 Nov 2024 //
BUSINESSWIRE
BridgeBio Publishes Infigratinib Study for Achondroplasia in NEJM
18 Nov 2024 //
GLOBENEWSWIRE
Acoramidis Shows Sustained Cardiovascular Benefit & Reduce in ACM
18 Nov 2024 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
BridgeBio To Show 42-Month Acoramidis Data At AHA 2024
03 Oct 2024 //
GLOBENEWSWIRE
Alnylam shares slide after heart drug data fails to impress investors
30 Aug 2024 //
REUTERS
BridgeBio Shares Data On Serum TTR Increase With Acoramidis
30 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Pharma to Participate in September Investor Events
28 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Launches MyAchonJourney Resource For Achondroplasia Families
19 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Reports Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Appoints Thomas Trimarchi As President And COO
23 Jul 2024 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10 Jun 2024 //
GLOBENEWSWIRE
BridgeBio To Participate In Goldman Healthcare Conference
06 Jun 2024 //
GLOBENEWSWIRE
BridgeBio Doses First KRASG12C NSCLC Patient With BBO-8520 In ONKORAS Trial
06 Jun 2024 //
BUSINESSWIRE
BridgeBio data show sustained benefit for achondroplasia drug
05 Jun 2024 //
BIOPHARMADIVE
BridgeBio: Durable Infigratinib Results In Achondroplasia Study
04 Jun 2024 //
GLOBENEWSWIRE
BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call
03 Jun 2024 //
GLOBENEWSWIRE
